ICU Medical/$ICUI
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About ICU Medical
ICU Medical is a California-based pure-play infusion therapy company that provides consumables, systems, and services for virtually every component of the IV continuum of care. ICU has become one of the largest players in its industry following its acquisition of Hospira Infusion Systems from Pfizer in 2017 and Smiths Medical from Smiths Group in 2022. It holds top-tier positions across its three reporting segments: consumables (50% of consolidated revenue), infusion systems (30%), and vital care (20%). The combined entity remains primarily US-focused, generating over 60% of its sales domestically.
- Ticker
- $ICUI
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 13,000
- Headquarters
- San Clemente, United States
- Website
- www.icumed.com
ICU Medical Metrics
BasicAdvanced
$4.2B
140.11
$1.20
0.76
-
Price and volume
Market cap
$4.2B
Beta
0.76
52-week high
$192.85
52-week low
$113.37
Average daily volume
242K
Financial strength
Current ratio
2.43
Quick ratio
0.996
Long term debt to equity
0.582
Total debt to equity
0.598
Interest coverage (TTM)
1.52%
Profitability
EBITDA (TTM)
326.124
Gross margin (TTM)
38.26%
Net profit margin (TTM)
1.39%
Operating margin (TTM)
5.78%
Effective tax rate (TTM)
3,574.48%
Revenue per employee (TTM)
$170,000
Management effectiveness
Return on assets (TTM)
1.93%
Return on equity (TTM)
1.41%
Valuation
Price to earnings (TTM)
140.111
Price to revenue (TTM)
1.936
Price to book
1.96
Price to tangible book (TTM)
42.26
Price to free cash flow (TTM)
28.859
Free cash flow yield (TTM)
3.47%
Free cash flow per share (TTM)
5.844
Growth
Revenue change (TTM)
-8.97%
Earnings per share change (TTM)
-179.79%
3-year revenue growth (CAGR)
-1.99%
10-year revenue growth (CAGR)
19.59%
3-year earnings per share growth (CAGR)
-15.87%
10-year earnings per share growth (CAGR)
-9.75%
What the Analysts think about ICU Medical
Analyst ratings (Buy, Hold, Sell) for ICU Medical stock.
Analyst projections of the future price of ICU Medical stock.
Bulls say / Bears say
Underlying demand is growing: second-quarter organic revenue rose 6%, with competitive wins, pump installations and consumables growth supporting the result. A larger installed pump base can also drive repeat sales of consumables. (ICU Medical, S&P Global Ratings)
Profitability is improving alongside growth: second-quarter gross margin reached 43%, up from 38% a year earlier, while adjusted EBITDA and adjusted EPS increased. ICU Medical also raised its full-year adjusted EBITDA and EPS guidance. (ICU Medical)
Cash generation and debt reduction are strengthening the balance sheet. S&P raised ICU Medical’s credit rating to BB from BB− after leverage fell and free operating cash flow exceeded its expectations, and it expects further organic growth and margin improvement. (S&P Global Ratings)
Reported revenue growth remains subdued: second-quarter sales rose only 1%, and S&P expects full-year 2026 revenue to fall about 2.5%, largely because the IV Solutions business was deconsolidated. Vital Care revenue also fell sharply year on year, leaving the headline growth picture weak despite stronger core businesses. (ICU Medical, S&P Global Ratings)
Regulatory and product-quality issues remain a material risk: an FDA warning letter concerning two pump models is still outstanding, and two more Class II product recalls were reported in October. Further testing or enforcement could delay products or add costs. (S&P Global Ratings, Yahoo Finance)
Tariffs, currency moves and freight costs continue to pressure margins. Management put annual tariff costs at $30 million to $40 million and also cited adverse currency and higher logistics expenses, which could offset some savings from operational improvements. (The Motley Fool)
Data summarised monthly by Lightyear AI. Last updated on 28 Oct 2026.
ICU Medical Financial Performance
Revenues and expenses
ICU Medical Earnings Performance
Company profitability
Upcoming events
No upcoming events
ICU Medical News
AllArticlesVideos
Funds containing ICU Medical
AllUSDEURGBP
Fund name | Fund size | $ICUI weighting |
|---|---|---|
iShares S&P SmallCap 600$IDP6 | $3.2B | 0.24% |
iShares S&P Small Cap 600£ISP6 | $3.2B | 0.24% |
SPDR Russell 2000 US Small Cap£R2SC | $5.3B | 0.14% |
SPDR Russell 2000 US Small Cap€R2US | $5.3B | 0.14% |
iShares MSCI USA Small Cap ESG Enhanced CTB€SXRG | $3.2B | 0.10% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.